tbuckley/cabot-search huggingface dataset:
Abstract 14032: A Randomized, Controlled Trial to Assess the Effects of Foods Containing Stearidonic Acid Soybean Oil on Eicosapentaenoic Acid Levels of Red Blood Cells and Omega-3 Index
Authors: Elaine Krul, Ratna Mukherjea, Glenna Hughes, Shawna L Lemke, Mary L Taylor, Daniel A Goldstein, Hong Su, Kevin C Maki
Journal: Circulation (2011)

Stearidonic acid (SDA) is a product of delta-6 desaturase, the rate-limiting enzyme in the conversion of alpha-linolenic acid (ALA) to eicosapentaenoic acid (EPA). Soybean oil enriched with SDA, produced through biotechnology, is a source of omega-3 fatty acids. Previous studies demonstrated an increase in %EPA in red blood cells (RBC) in people consuming SDA-enriched soybean oil or SDA ethyl esters. The objective of the present study was to evaluate the efficiency of SDA, when incorporated as a food ingredient, on EPA enrichment of RBC membranes and the omega-3-index in men and women. Healthy subjects (N=127) were randomized to three diet interventions and 108 subjects completed the 12-wk study. Treatments were: 1) 1.5 g/d of high-oleic sunflower oil (HOSO) by capsule and food containing HOSO (Control); 2) 1.5 g/d of EPA ethyl ester by capsule and food containing HOSO (EPA); and, 3) 1.5 g/d of HOSO by capsule and food containing SDA soybean oil (SDA). Food sources provided 7.5 g/d of oil in two baked bars and one beverage daily. The SDA and EPA groups provided 1.6 g SDA/d and 1.35 g EPA/d, respectively. No treatment-specific adverse events were observed. Data were analyzed by repeated-measures analysis of variance. Mean %EPA in RBC were 0.5, 2.17, and 0.85% for Control, EPA and SDA groups and were significantly greater for EPA and SDA compared to Control (P 0.05) among all treatment groups. This study confirmed that significant increases in RBC EPA could be achieved through consumption of foods easily formulated to contain SDA-enriched soybean  .
Abstract 8613: Load-Independency of the 2D Speckle Tracking-Derived Left Ventricular Twist and Apex-to-Base Rotation Delay in Longstanding, Non-Ischemic Dilated Cardiomyopathy
Authors: Hyung-Kwan Kim, Sung-A Chang, Dong-Ho Shin, Ji-Hyun Kim, Seung-Pyo Lee, Yong-Jin Kim, Goo-Yeong Cho, Dae-Won Sohn, Byung-Hee Oh, Young-Bae Park
Journal: Circulation (2011)

Background: Although Left ventricular(LV) twist is known to be load-dependent in healthy volunteers, this has not been examined in patients with dilated cardiomyopathy(DCMP), in whom alterations in myofiber architecture and its arrangement could perturb the intrinsic dependence of LV twist on loading conditions. This study tried to examine whether LV twist remains load-dependent in DCMP. Methods: 34 DCMP patients with a baseline LV ejection fraction of &lt;40% were enrolled. After baseline measurements, pneumatic compression of the lower extremities(Pcom) was employed to increase LV afterload. Subsequently, sublingual nitroglycerin(SL-NG) was administered to modify preload. Conventional echocardiographic parameters, LV end-systolic wall stress(LV-ESWS), LV twist, and apex-to-base-rotation delay were assessed under each condition. Results: Although LV-ESWS significantly increased under Pcom(196.9±64.9 at baseline vs. 231.8±78.9g/m 2 under Pcom, P &lt;0.017) and decreased after SL-NG(231.8±78.9 under Pcom vs. 197.4±67.4g/m 2 after SL-NG, P &lt;0.017), LV twist and apex-to-base rotation delay showed no significant changes with modification of LV loading condition(for LV twist, 7.78±4.63° at baseline vs. 7.19±4.34° under Pcom vs. 7.41±4.46 after SL-NG, P =0.65; for apex-to-base rotation delay, 16.56±13.81 at baseline vs. 17.19±14.81 under Pcom vs. 15.95±13.27 after SL-NG, P =0.53). Careful examination of individual patient data revealed that LV twist was load-independent when patients had a LV twist &lt;12°. Apex-to-base rotation delay was also found to be load-independent, but only in patients with a LV ejection fraction &lt;34%. Conclusion: LV twist and its component, apex-to-base rotation delay, had relatively load-insensitive properties in patients with longstanding DCMP, and can be used in future clinical trial as load-independent LV dyssynchrony indexes.
Euthanasia: where the Netherlands leads will the world follow?
Authors: E. J Emanuel
Journal: BMJ (2001)

Euthanasia and, to a much lesser extent, physician assisted suicide have been socially accepted and openly practised in the Netherlands for about two decades. The Netherlands' recent legalisation of euthanasia1 merely codifies what already exists and is unlikely to change Dutch practices significantly. The one exception may be to permit a few more cases of euthanasia among children aged 12–18 years. But drawn out deaths in this age group, predominantly from cancer or AIDS, are rare, accounting for fewer than 400 deaths (<0.2% of all deaths) a year in all of the Netherlands. The key question is not whether things will change in the Netherlands, but whether legalisation of euthanasia and physician assisted suicide there will stimulate a trend in other developed countries.

This seems highly unlikely. Certainly in the United States, no state other than Oregon seems poised to take the opportunity presented by the 1997 Supreme Court ruling to legalise euthanasia or physician assisted suicide. Indeed, in the past five years 10 states have passed bills making euthanasia or physician assisted suicide illegal, …
Abstract 3794: Impact of Gender and Prodromes on Outcome in Acute Coronary Syndromes: A Population-Level Analysis
Authors: Michelle M Graham, Paul W Armstrong, Becky Leung, Padma Kaul
Journal: Circulation (2009)

Background: We determined the rates at which acute coronary syndrome (ACS) patients seek medical attention for non-specific prodromal symptoms, as well as whether sex differences and an association...
Abstract 755: Ten-year Survival in Patients with Type A Aortic Intramural Hematoma
Authors: Takeshi Kitai, Shuichiro Kaji, Kite Kim, Yoshimori An, Takafumi Yamane, Natsuhiko Ehara, Minako Katayama, Makoto Kinoshita, Atsushi Kobori, Koichi Tamita, Atsushi Yamamuro, Tomoko Tani, Shigefumi Morioka, Yutaka Furukawa
Journal: Circulation (2008)

Recent studies have demonstrated that short and mid-term prognosis of type A acute aortic intramural hematoma (IMH) is remarkably better than classic aortic dissection (AD). The distinctive pathology of IMH from classic AD may account for such difference. However, it is uncertain if the prognosis of IMH remains favorable during long-term (ten-year) follow-up. The purpose of this study was to clarify the long-term prognosis of type A IMH. A total of 432 patients with acute aortic syndrome were admitted to our institution from 1989 to 2006. Of these patients, there were 42 patients with type A IMH and 201 patients with classic type A AD. In-hospital and long-term outcomes of the 42 patients with type A IMH were evaluated. Mean age of the patients was 66±10 at baseline and 25 patients were female. Mean follow-up period was 7.6 years. Emergent surgical repair was performed in 11 patients due to complication including cardiac tamponade, aortic regurgitation and aortic dilatation; while 31 patients were treated with initial medical therapy. Nine patients who demonstrated progression to AD or increase in size of hematoma underwent surgical repair except for 2 patients who refused surgery and died of aortic rupture. In-hospital mortality rate of all 42 IMH patients was 4%. There were 3 late deaths and the causes of death were pneumonia, renal failure, and heart failure. The actuarial survival rates were 95, 95 and 87% at 1, 5 and 10 years. Medical treatment alone was not enough to manage all type A IMH patients and almost a half of the patients needed surgical intervention. However, type A IMH patients who were treated medically with surgical repair in cases with complications have favorable long-term (ten-year) prognosis.
Cardiac sarcoidosis
Authors: D N Mitchell, R M du Bois, P J Oldershaw
Journal: BMJ (1997)

Cardiac arrhythmias and sudden death are likely among patients known to have cardiac lesions from sarcoidosis. Other clinical presentations include conduction defects, congestive heart failure, and a picture suggesting myocardial infarction–but the first evidence of cardiac sarcoidosis may be provided by a pathologist after the sudden death of someone who had been completely free of symptoms.1

Attempts have been made to assess the prevalence of cardiac sarcoidosis. Mikhail et al studied 147 consecutive patients presenting with sarcoidosis and found 14 with electrocardiographic abnormalities; 10 of these had no symptoms related to the heart.2 Stein et al surveyed 80 selected patients aged under 40 years, of whom only five were white and 47 had chronic disease.3 Electrocardiographic abnormalities of conduction or repolarisation were detected in 41 of these 80 patients, none of whom had cardiac symptoms.

In two other large series of unselected patients the proportion with clinical evidence of granulomatous changes in the heart was small. Scadding and Mitchell reported that, of 500 consecutive patients under their care, only four showed such evidence.1 In the series of 702 …
Abstract 14890: Hyponatremia Associated with Flecainide: Case Series
Authors: Shahid Qamar, Wael Hassan, Jasbir Sra, Masood Akhtar, M. Eyman Mortada
Journal: Circulation (2012)

Introduction: Flecainide is a Class IC antiarrhythmic agent; its primary electrophysiologic effect is to block fast, inward sodium current, thereby prolonging the refractory period and slowing cond...
Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation
Authors: Christian T. Ruff, Robert P. Giugliano, Eugene Braunwald, Michele Mercuri, Valentin Curt, Joshua Betcher, Laura Grip, Abby L. Cange, Andrea E. Crompton, Sabina A. Murphy, Naveen Deenadayalu, Elliott M. Antman
Journal: Journal of the American College of Cardiology (2014)
Maintaining privacy and the health of the public
Authors: J. P Vandenbroucke
Journal: BMJ (1998)

By a twist of irony one of America's foremost resources of clinical and epidemiological research has been struck by a growing concern about patient privacy.1 Since the early 1900s the Mayo Clinic Foundation at Rochester, Minnesota, has maintained a medical record system that amounts to a population registry on health and disease.2 Hundreds of clinical, biochemical, and epidemiological research papers have used old records and added new analyses or follow up data. Recent legislation in the state of Minnesota has made such use next to illegal. Minnesota is not the only place where privacy legislation is jeopardising the use of patient data for research. It is time to reassess the terms of the privacy debate.

In response to the Minnesota law the New England Journal of Medicine has devoted no fewer than four pages to a cry from the heart from Rochester.1 The Mayo Clinic Foundation is setting up a heroic effort to obtain “broad informed consent” from all patients for future use of their data. Predictably, this will fall short of the requirements of those who demand specific informed consent for each piece of research—even retrospectively.3 The mere possibility of litigation recently prevented the description of an epidemic of drug resistant tuberculosis …
Folie a famille: shared paranoid disorder in a Vietnam veteran and his family
Authors: J N Glassman, M Magulac, D F Darko
Journal: American Journal of Psychiatry (1987)

Reports of folie à famille are rare; this may be the first reported case involving a Vietnam veteran. Expression of his paranoid schizophrenia involved delusions and hallucinations relating to Vietnam, and his wife and children shared his paranoia. Typical of folie à famille were the dominant family member, the threat of violence, and the family's social isolation, frequent crises, and stable membership. Although the veteran's intrusive recollections of his Vietnam experience were typical of posttraumatic stress disorder, he acted on rather than avoided them. Treatment focused on the entire family, partly to minimize future problems in the children.
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelial Function, and Inflammation
Authors: Giuseppe Patti, Domenico Grieco, Giordano Dicuonzo, Vincenzo Pasceri, Annunziata Nusca, Germano Di Sciascio
Journal: Journal of the American College of Cardiology (2011)
The importance of age as a prognostic factor in corpus cancer
Authors: A. Husain, N. Karnik Lee, M. K. Cheung, K. Osann, L. M. Chen, J. K. Chan
Journal: Journal of Clinical Oncology (2006)

15005 Background: To determine the prognostic factors that influence the survival of younger women diagnosed with uterine cancers. Methods: Patients with a diagnosis of uterine cancer were isolated from the Surveillance, Epidemiology, and End Results (SEER) cancer database from 1988–2001 and demographic and clinico-pathologic data were collected. Patients in the database were stratified by age at diagnosis into two age groups: ≤40and &gt;40 years old. Disease specific survival was calculated using Kaplan-Meier estimates. Results: Of the 51,471 women diagnosed with uterine cancer in the study period, 2076 patients were ≤40 and 49,395 were &gt;40 years old. The mean age in the younger group was 35.6 and that of the older group was 65.2. The overall distribution by stage was Stage I-76%, II-8%, III-7% and IV-9%. Younger patients were more likely to be non-white (30% vs 18%, p &lt; 0.05), have earlier stage disease (79% vs 75%, p &lt; 0.05), grade 1 lesions (48% vs 36%, p &lt;0.05) and sarcomas (16% vs 8%) compared to their older counterparts. The overall disease specific 5-year survival demonstrated that younger patients (≤40 years old) had a significantly improved survival prognosis in comparison to older women (93% versus 86%; p &lt; 0.0001). This survival difference remains significant after adjusting for stage, race, surgical treatment, and radiation treatment. Subgroup analysis revealed no statistical difference in outcome between the two age groups for patients with clear cell histology. There also was no statistical significance in survival for patients with grade 2 or 3 lesions and advanced stage disease. Conclusions: Our large population based study demonstrates that younger patients (≤40) have an overall survival advantage compared to women &gt;40 years. This difference remains significant when adjusted for stage, race, surgical treatment, and radiation treatment. Women with clear cell cancers of the uterus appear to have a poor prognosis independent of age. No significant financial relationships to disclose.
Abstract 1770: Proteasome Switching is Associated with Adverse Cardiac Remodeling in a Transgenic Mouse Model of Sustained Inflammatory Signaling
Authors: Wei Wang, Gabor Szalai, Natarajan Sivasubramanian, Douglas L Mann
Journal: Circulation (2008)

The 26S proteasome possess proteolytic activity and deubiquitinating (DUB) activity of ubiquitin tagged proteins. Whereas the proteolytic activity of the 26S proteasome facilitates protein degradation, proteasome DUB activity spares proteins from degradation by shortening the length of the ubiquitin chains, thereby preventing proteins from being degraded by the 26S proteasome. In yeast, increased DUB activity is beneficial by preventing depletion of ubiquitin pools critical for cell signaling. However, the role of DUB activity in mammalian systems is not known. We have shown that mice with cardiac restricted overexpression of tumor necrosis factor (sTNF mice) develop a heart failure phenotype characterized by progressive left ventricular (LV) remodeling and accumulation of pro-apoptotic proteins, including Smac/Diablo. To determine whether the adverse LV remodeling in sTNF mice was related to alterations in DUB activity we measured the cleavage of ubiquitin-AMC, an in vitro fluorescent substrate for DUBs, in purified preparations of the 26S proteasome obtained from hearts of 4 week old sTNF and littermate (LM) control mice. Compared to LM controls we observed a significant (p &lt; 0.001) 60.8% decrease in activity of the 26S proteasome and a significant (p &lt; 0.01) 24.2% increase in DUB activity in sTNF mouse hearts. There was also a significant (p &lt; 0.01) 11-fold increase myocardial protein levels of USP14, a critical DUB associated with the 26S proteasome in sTNF mouse hearts. The decrease in 26S proteasome activity and increased DUB activity in sTNF mouse hearts was accompanied by an increase in myocardial levels of ubiquitinated SMAC/Diablo. Taken together these results show for the first time that sustained myocardial inflammation leads to switch in the function of the proteasome from a proteolytic function to a protein sparing function. Although this “proteasome switching” may provide a short-term adaptive benefit by preventing depletion of critical ubiquitin pools, it may lead to long-term maladaptive consequences by allowing the progressive accumulation of potentially harmful pro-apoptotic proteins in the cytosol, which may in turn promote programmed cell death and adverse cardiac remodeling.
Abstract 1692: The Impact of Hypertriglyceridemia on Clinical Outcome of Patients Subjected to Percutaneous Coronary Intervention in the Presence of High and Low High-Density Lipoprotein Cholesterol
Authors: Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, Petros Okubagzi, Augusto Pichard, William Suddath, Kenneth Kent, Lowell Satler, Ron Waksman, H. Bryan Brewer
Journal: Circulation (2008)

Background: High-density lipoprotein cholesterol (HDLc) is known to have protective cardiovascular effects. Elevated triglycerides (TRI) are often targeted with therapeutic agents. This study aimed to investigate the effects of TRI in the presence of high and low levels of HDLc on clinical outcomes of patients undergoing contemporary percutaneous coronary intervention (PCI). Methods: We analyzed a series of 4391 patients who presented for elective contemporary PCI since 2003 and have completed 1-year clinical follow up. The study cohort comprised of 4 subgroups: high TRI with high HDLc, high TRI with low HDLc, normal TRI with high HDLc, and normal TRI with low HDLc. High TRI was defined as ≥ 200 mg/dl, normal TRI as &lt; 200 mg/dl, high HDLc was defined as ≥ 40mg/dl for males and ≥ 45mg/dl for females, and low HDLc as &lt; 40mg/dl for males and &lt; 45mg/dl for females. The assessed endpoints, death, Q-wave myocardial infarction (Q wave MI), target vessel revascularization (TVR), and a composite of major adverse cardiac events (MACE) were then compared between groups. Results Approximately 98.1% of the overall population is on statin therapy. As expected, patients with high HDLc have significantly better outcomes as compared to those with low HDLc and normal TRI; however, the high TRI low HDLc group demonstrated similar outcomes to patients with high HDLc and normal TRI. Additionally, among the group with high TRI, there were no significant differences in 1-year MACE outcomes between tertiles of non-HDL cholesterol. (Table ) Conclusion: In patients undergoing PCI with normal triglycerides low HDLc was associated with increased MACE and death at 1 year when compared to high HDLc patients. In contrast, a similar incidence of death and MACE was observed in hypertriglycer-idemic patients with low HDLc and high HDLc levels. Therapies targeted to elevate HDLc among patients with normal TRI may play a critical role in the prevention of recurrent cardiac events post PCI. Table: 1 Year Outcomes
The incidence of seizures among children with autistic symptoms
Authors: Eva Y. Deykin, Brian MacMahon
Journal: American Journal of Psychiatry (1979)

The authors examined 183 children with autistic symptoms and found that the age-specific incidence rates of seizures in this sample were between 3 and 28 times the rates for children in the general population. The subjects classified as totally autistic were at high risk of developing seizure from early childhood well into adolescence, but especially so at puberty. The partially autistic children had an increased risk of seizures only up to age 10. The authors suggest that the high incidence of seizures at puberty observed in this study may be specific to children with total autistic symptomatology and may represent a distinct pathological process associated with autism.
Abstract 17797: Protective Role of Angiotensin-(1-7) Receptor Mas on Kidney Fibrosis
Authors: Sergio V Pinheiro, Anderson J Ferreira, Júnio A Magalhães, Kátia D da Silveira, Beatrix Fauler, Natalia S Assis, Jose Ricardo B Lopes, Marcus Vinicius M Andrade, Rodolfo Lisboa, Gregory T Kitten, Sérgio Henrique S Santos, Robson A Santos, Ana Cristina S Silva
Journal: Circulation (2011)

Angiotensin (Ang) II is involved in inflammatory and fibrotic mechanisms of cardiovascular and renal diseases. Ang-(1-7) counterbalances most of the Ang II pathophysiological effects. However, a protective role for Ang-(1-7) in kidney fibrosis remains speculative. To evaluate the role of Ang-(1-7) receptor Mas on pathophysiological mechanisms of kidney fibrosis we used a distinct genetic background of Mas-knockout mice (FVB/N MasKO). Urine and plasma samples were collected for measuring renal function parameters. Kidneys were harvested for histology, confocal immunofluorescence of matrix proteins, RT-PCR of AT1 receptor and TGF-beta and TUNEL apoptosis. Compared with wild-type controls, MasKO mice have reduced 24h-urine volume (0.75±0.15 vs. 1.51±0.33mL p&lt;0.05) and sodium fractional excretion (1.09±0.21 vs. 2.16±0.45% p&lt;0.05), without changes in osmolal and free-water clearances. The 1.8-fold higher creatinine clearance (7.11±1.25 vs. 3.92±0.48µL.min.g -1 p&lt;0.05) and the 2.9-fold increase in albuminuria (3.42±0.56 vs. 1.17±0.27µg.g -1 p&lt;0.05) detected in MasKO mice suggest glomerular hyperfiltration. Histology showed variable degrees of mesagial cells proliferation and segmental glomerulosclerosis, with an increased index of glomerular lesion in MasKO (0.56±0.08 vs. 0.25±0.10 p&lt;0.05). These findings were associated with increased glomerular content of collagens I and IV, fibronectin, Ang II and upregulation of mRNA for AT1 receptor and TGF-beta. TUNEL staining revealed a 2-fold augmentation in fluorescence of apoptotic nuclei from glomerular and tubular cells in MasKO. Our results suggest that Mas receptor may exert protective role on renal fibrosis and apoptosis, possibly counterbalancing Ang II and TGF-beta effects in the kidney.